Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
Manual marking, digital marking, manual and digital marking—toric IOL alignment methods continue to be an important topic. Both methods still have a place, and both have their pros and cons. Four physicians discussed their preferences.
➤ Fast Track designation granted to one-time intravitreal gene therapy for geographic atrophy ➤ FDA clears IND for Stargardt gene therapy to move forward into a Phase 1/2 clinical trial ➤ BLA submission for retinitis pigmentosa gene therapy begins ➤ First patient dosed in Phase 1/2 trial evaluating NK therapy ➤ Enrollment complete in Phase 2b trial for PCED therapy ➤ ASCRS news and events
The University of Chicago ophthalmology residents reviewed “Comparative evaluation of clinical results and patient-reported outcomes of enhanced monofocal and conventional monofocal intraocular lenses” from the Journal of Cataract & Refractive Surgery.
Since its approval, the Light Adjustable Lens (LAL, RxSight) has become well known for the successful outcomes that it can provide for patients. Four ophthalmologists shared their experience with the product and what they’ve learned about limitations, how to work through challenges, and more.
Ophthalmology is constantly evolving to meet new and unmet needs. EyeWorld asked members of its Cataract Editorial Board and the ASCRS Cataract Clinical Committee to weigh in on: If I could ask industry to produce one new product, this is what it would be and why.
Three surgeons weighed in on the pros and cons of different lens materials as well as what may be coming in the future.
➤ Initial Phase 3 results for dry eye disease therapy ➤ Positive Phase 2 results for intravitreal implant for glaucoma and diabetic retinopathy ➤ Phase 1/2a results from allogenic cell therapy for geographic atrophy ➤ Phase 1 trial successful with oral treatment for non-proliferative diabetic retinopathy ➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events